Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Berlin - Delayed Quote EUR

Akeso Inc (4RY.BE)

11.40
+0.90
+(8.57%)
As of 1:09:05 PM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 4RY.BE

Recent News: 4RY.BE

View More
Akeso and Summit notch another Phase III win with their Keytruda competitor

Akeso and Summit notch another Phase III win with their Keytruda competitor
Clinical Trials Arena 26 minutes ago
Why Is Summit Therapeutics Stock Soaring On Wednesday?

Why Is Summit Therapeutics Stock Soaring On Wednesday?
Benzinga 16 hours ago
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy

Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy
PR Newswire yesterday
Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
PR Newswire 6 days ago
3 Asian Stocks Estimated To Be Up To 42.1% Below Intrinsic Value

3 Asian Stocks Estimated To Be Up To 42.1% Below Intrinsic Value
Simply Wall St. 6 days ago
Asian Growth Stocks With High Insider Ownership In April 2025

Asian Growth Stocks With High Insider Ownership In April 2025
Simply Wall St. 6 days ago
The Chinese CEO Who Believes Her Cancer Drug Can Beat Merck’s Bestseller

The Chinese CEO Who Believes Her Cancer Drug Can Beat Merck’s Bestseller
The Wall Street Journal 12 days ago
High Growth Tech Stocks In Asia To Watch March 2025

High Growth Tech Stocks In Asia To Watch March 2025
Simply Wall St. 24 days ago
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies

Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
PR Newswire 24 days ago
Akeso to Host 2024 Full-Year Financial Results and Corporate Update Call on Monday, March 31, 2025

Akeso to Host 2024 Full-Year Financial Results and Corporate Update Call on Monday, March 31, 2025
PR Newswire 26 days ago
Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
PR Newswire last month
View More